Number (%) of participants and unacceptable responses in domestic external quality assessment for whom the intended responses were a single antibody (2016 to 2020)
| Year | Trial | Specimen | Intended response | No. of participants | Acceptable (%) | Unacceptable (%) | Unacceptable responses (N) |
|---|---|---|---|---|---|---|---|
| 2016 | 1st | BBS-16-01 | Anti-Fy(a) | 118 | 115 (97.5) | 3 (2.5) | Anti-Fy(a)+anti-N (2) Anti-E (1) |
| 2017 | 1st | BBS-17-01 | Anti-C | 122 | 119 (97.5) | 3 (2.5) | Anti-C+anti-S (2) Anti-E (1) |
| 2017 | 2nd | BBS-17-04 | Anti-c | 123 | 109 (88.7) | 14 (11.3) | Anti-c+anti-E (11) Anti-c+anti-Jk(b) (1) Not detected (2) |
| 2019 | 2nd | BBS-19-05 | Anti-c | 132 | 116 (87.9) | 16 (12.1) | Anti-c+anti-E (14) Anti-E (1) Anti-K (1) |
| 2020 | 2nd | BBS-20-04 | Anti-E | 135 | 133 (98.5) | 2 (1.5) | Anti-c+anti-E (2) |